By Bill Berkrot(Reuters) - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.The Lilly drug, dulaglutide, achieved the primary goal of the 599-patient study by demonstrating so-called non-inferiority to the highest approved dose of Victoza after 26 weeks, according to initial results released by the company on Tuesday.
Biogen Idec Inc’s (NASDAQ:BIIB) Alzheimer’s drug candidate, BIIB037, showed promise in its Phase Ib testing, so much so that the company has decided to push the drug directly into Phase III trials, skipping Phase II trials, the company announced early morning Tuesday at the 2014 Deutsche Bank BioFEST Conference.
Eli Lilly and Co (LLY) won the US Food and Drug Administration’s (FDA) approval yesterday for its latest diabetes medication, Trulicity. The drug will be used as a supplement for the treatment of type-2 diabetes in adults, and will require exercise and diet control. However, due to safety concerns, the approval comes with a clause that requires Eli Lilly to conduct post-marketing studies to establish Trulicity’s safety profile.
NEW DELHI: Three new type-2 diabetes medicines, two of which were recently launched in India, have come under the scanner of the US drug regulator for potential risk of causing acidosis that could require hospitalization. The US Food and Drug Administration (FDA) has warned medical professionals and patients that type-2 diabetes medicines - canagliflozin, dapagliflozin, and empagliflozin - may cause high levels of blood acids which can lead to serious adverse effects.
Hundreds of scientists sifting through genetic data from 122,000 people have quintupled the number of gene variants known to boost the risk of diabetes, a pair of studies released Sunday reported.A consortium of researchers first isolated 10 gene mutations that help determine the body's ability to regulate blood sugar and insulin levels, the key factors underlying type 2 diabetes.
Mylan Inc. (MYL) has become a tough competitor in the biosimilar glargine race after announcing that it will begin Phase-III trials to show the non-inferiority of its experimental drug glargine when compared to Sanofi SA’s (SNY) diabetes drug Lantus.
Lantus generated revenue of $7.6 billion in fiscal year 2013. It and Mylan’s experimental drug will be used to treat type 2 diabetes mellitus patients.
Pfizer Inc.’s (NYSE:PFE) Ibrance, developed for the treatment of advanced (metastatic) breast cancer received US Food and Drug Administration's (FDA) accelerated approval on Tuesday. The FDA’s final approval for the drug has come two months prior to the expected approval date.
A new study indicating overdose deaths have risen in close parallel with the country’s soaring consumption of prescription narcotics is more evidence the painkillers have become Canada’s most dangerous drugs after tobacco and alcohol — and need concerted, national action, says a leading addiction researcher.
As the flu rages through our population, many people will run to their doctors hoping for the miracle of modern medicine. When doctors see a patient with symptoms of the flu they often prescribe a drug known as Tamiflu, known generically as Oseltamivir. Tamiflu is a nuraminidase inhibitor, which means it blocks the actions of a protein that is essential for the flu virus to make copies of itself.